Regado Biosciences, a spinout from the Duke University Medical Centers surgery department, is now a division of Allergan which firm acquired Regardo/Tobira in September 2016. In 2015 Regado Biosciences Inc., - at the time a public tarded anti-thrombotics company - and private biotech Tobira Therapeutics Inc. (hepatic and infectious diseases) reverse merged. The resulting entity was renamed Tobira engaged in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Regados paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a per patient, per setting basis. Regados clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Anticoagulants represent an established multi-billion dollar worldwide market opportunity in need of therapeutics with improved safety and flexibility, which optimize therapeutic outcomes. The company owns or has pending patent protection for worldwide rights to all of its development products, which, for the anticoagulant systems REG1 and REG2, extend through 2025 and beyond. Additionally, Regado has an exciting pipeline of aptamer-control agent pairs against platelet adhesion and/or platelet aggregation targets that recently resulted in the nomination of REG3 as a clinical development ca
